Oncopeptides has a poster presentation of data from its Phase 1/2 O-12-M1 study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago. The study evaluates melflufen in the treatment of relapsed/refractory multiple myeloma (RRMM), Melflufen is a lipophilic peptide-conjugated alkylator belonging to the novel class of Peptidase Enhanced Cytotoxics (PEnC).
The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and dexamethasone in the Phase 1/2 clinical study named O-12-M1. TTNT is used in Real World Evidence to assist treatment decisions and support economic reimbursement modeling.
Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM). Presenter: Paul G. Richardson, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Session: Hematologic Malignancies—Plasma Cell Dyscrasia Date/Time: Monday, June 3, 8:00-11:00 a.m. Central Location: Hall A (Poster #369) Abstract number 8043